PBK and Miyoshi myopathy: Activating mutations in the NF‐κB pathway are also known to drive MM.44 OTS514 treatment caused a marked decrease in the phosphorylated form of IκBα in four of the five HMCLs examined, indicating that TOPK inhibition also suppresses the canonical NF‐κB pathway and its MM‐supportive targets.